Clinical Trial Update: A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 study results for TAK-063 in acute exacerbation of schizophrenia have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• TAK-063 (TAK-063)

Snippet

Sponsor: Takeda | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2017-09-29